-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Repare Therapeutics Inc. (NASDAQ:RPTX) Receives $30.80 Average PT From Analysts
Repare Therapeutics Inc. (NASDAQ:RPTX) Receives $30.80 Average PT From Analysts
Shares of Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $30.80.
A number of research analysts recently weighed in on the stock. HC Wainwright dropped their price objective on shares of Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, November 17th. Capital One Financial assumed coverage on shares of Repare Therapeutics in a report on Friday. They issued an "overweight" rating and a $28.00 price objective for the company.
Get Repare Therapeutics alerts:Repare Therapeutics Price Performance
Shares of RPTX opened at $14.25 on Friday. Repare Therapeutics has a 1-year low of $8.06 and a 1-year high of $19.24. The stock has a market cap of $597.96 million, a PE ratio of -19.52 and a beta of 0.11. The firm has a 50-day simple moving average of $15.53 and a two-hundred day simple moving average of $13.95.
Repare Therapeutics (NASDAQ:RPTX – Get Rating) last announced its quarterly earnings results on Wednesday, November 9th. The company reported $1.71 earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $1.91. Repare Therapeutics had a negative net margin of 21.31% and a negative return on equity of 9.53%. The business had revenue of $112.55 million during the quarter, compared to analysts' expectations of $43.23 million. As a group, sell-side analysts expect that Repare Therapeutics will post -0.69 earnings per share for the current fiscal year.Insider Activity at Repare Therapeutics
In related news, Director Davis Jerel sold 250,000 shares of Repare Therapeutics stock in a transaction that occurred on Friday, December 9th. The shares were sold at an average price of $16.00, for a total value of $4,000,000.00. Following the completion of the transaction, the director now owns 2,094,451 shares in the company, valued at $33,511,216. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 33.60% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in RPTX. Bartlett & Co. LLC purchased a new position in Repare Therapeutics in the second quarter worth approximately $28,000. UBS Group AG lifted its position in shares of Repare Therapeutics by 26.3% during the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock worth $43,000 after buying an additional 739 shares during the last quarter. Bpifrance SA purchased a new stake in shares of Repare Therapeutics during the 2nd quarter worth approximately $113,000. Tower Research Capital LLC TRC purchased a new stake in shares of Repare Therapeutics during the 3rd quarter worth approximately $113,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Repare Therapeutics during the 3rd quarter worth approximately $143,000. Hedge funds and other institutional investors own 78.19% of the company's stock.
Repare Therapeutics Company Profile
(Get Rating)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Read More
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Which Streaming Service Stock is Best in 2023?
- Here's Why Snap Stock Can Double in 2023
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $30.80.
MarketBeat.com 報導,瑞帕爾治療公司(NASDAQ:RPTX-獲取評級)的股票已經從目前覆蓋該公司的六家評級公司中獲得了「中等購買」的共識評級。一位分析師對該股票進行了保留評級,其中五名分析師為該公司分配了買入評級。在去年更新了股票覆蓋率的分析師中,平均 12 個月的價格目標為 30.80 美元。
A number of research analysts recently weighed in on the stock. HC Wainwright dropped their price objective on shares of Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, November 17th. Capital One Financial assumed coverage on shares of Repare Therapeutics in a report on Friday. They issued an "overweight" rating and a $28.00 price objective for the company.
一些研究分析師最近對股票進行了權衡。韋賴特 HC 溫賴特將其對 Repel 治療藥物股票的價格目標從 38.00 美元降至 25.00 美元,並在 11 月 17 日(星期四)的一份報告中為該公司設定了「買入」評級。第一資本金融在週五的一份報告中承擔 Repin 治療的股份覆蓋率。他們為公司頒布了「超重」評級和 28.00 美元的價格目標。
Repare Therapeutics Price Performance
雷普雷治療藥物價格表現
Shares of RPTX opened at $14.25 on Friday. Repare Therapeutics has a 1-year low of $8.06 and a 1-year high of $19.24. The stock has a market cap of $597.96 million, a PE ratio of -19.52 and a beta of 0.11. The firm has a 50-day simple moving average of $15.53 and a two-hundred day simple moving average of $13.95.
RPTX 的股票在上週五開盤 14.25 美元。雷普雷治療藥物的價格為 8.06 美元的 1 年低點和 1 年高點 19.24 美元。該股的市值為 59796 萬美元,私募股比率為 -19.52,測試值為 0.11。該公司有一個 50 天的簡單移動平均線 15.53 美元和兩百天的簡單移動平均線為 13.95 美元。
Insider Activity at Repare Therapeutics
在雷普雷治療的內幕活動
In related news, Director Davis Jerel sold 250,000 shares of Repare Therapeutics stock in a transaction that occurred on Friday, December 9th. The shares were sold at an average price of $16.00, for a total value of $4,000,000.00. Following the completion of the transaction, the director now owns 2,094,451 shares in the company, valued at $33,511,216. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 33.60% of the company's stock.
在相關新聞中,導演戴維斯·傑雷爾出售 250,000 股 Reparel 治療股票在 12 月 9 日(星期五)發生的交易中。股票以 16 美元的平均價格出售,總價值為 4,000 萬美元。交易完成後,董事現在擁有該公司 2,094,451 股股份,價值 33,511,216 美元。出售是在與證券交易委員會的法律文件中披露的,可以通過以下方式訪問 此超連結。公司內部人士擁有公司股票的 33.60%。
Institutional Inflows and Outflows
機構流入和流出
A number of institutional investors have recently added to or reduced their stakes in RPTX. Bartlett & Co. LLC purchased a new position in Repare Therapeutics in the second quarter worth approximately $28,000. UBS Group AG lifted its position in shares of Repare Therapeutics by 26.3% during the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock worth $43,000 after buying an additional 739 shares during the last quarter. Bpifrance SA purchased a new stake in shares of Repare Therapeutics during the 2nd quarter worth approximately $113,000. Tower Research Capital LLC TRC purchased a new stake in shares of Repare Therapeutics during the 3rd quarter worth approximately $113,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Repare Therapeutics during the 3rd quarter worth approximately $143,000. Hedge funds and other institutional investors own 78.19% of the company's stock.
一些機構投資者最近增加或減少了他們在 RPTX 的賭注。巴特利特 & 有限公司有限責任公司在第二季度購買了一個新的位置,價值約為 28,000 美元。瑞銀集團股份公司在第三季度提升了 26.3% 的瑞寶治療股份地位。上一季度再購買 739 股股份後,瑞銀集團股份公司現在擁有該公司股票價值 43,000 美元的 3,551 股。Bpifrance SA 在第二季度購買了價值約 113,000 美元的 Repis 治療藥物股份的新股份。塔研究資本有限責任公司 TRC 在第三季度購買了 Repis 治療藥物股份的新股份,價值約為 113,000 美元。最後,福克斯運行管理有限責任公司在第三季度購買了 Repel 治療藥物股份的新股份,價值約為 143,000 美元。對沖基金和其他機構投資者擁有公司股票的 78.19%。
Repare Therapeutics Company Profile
雷普雷療法公司簡介
(Get Rating)
(取得評分)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Repare Therapetics Inc 是一家臨床階段的精密腫瘤學公司,通過在加拿大和美國使用其合成致死性方法來發現並開發治療藥物。該公司使用其 SniprX,這是一個專有的,全基因組且支持 CRISPR 的平台,系統地發現和開發高度針對性的癌症療法,該療法專注於基因組不穩定性,包括 DNA 損傷修復。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Which Streaming Service Stock is Best in 2023?
- Here's Why Snap Stock Can Double in 2023
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- 獲取有關雷帕爾治療研究報告(RPTX)的免費副本
- 李汽車會成為 2023 年中國最不討厭的電動車股票嗎?
- 2023 年哪個流媒體服務股票最好?
- 這就是為什麼快照股票在 2023 年可以翻倍
- 市場節拍:評論中的一周
- 為什麼群眾罷工股票價格掙扎?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Repel 治療的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 RepARE 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧